Search results for "Hormonal"

showing 10 items of 136 documents

Endometrial Receptivity Analysis (ERA): data versus opinions

2021

Abstract This article summarises and contextualises the accumulated basic and clinical data on the ERA test and addresses specific comments and opinions presented by the opponent as part of an invited debate. Progress in medicine depends on new technologies and concepts that translate to practice to solve long-standing problems. In a key example, combining RNA sequencing data (transcriptomics) with artificial intelligence (AI) led to a clinical revolution in personalising disease diagnosis and fostered the concept of precision medicine. The reproductive field is no exception. Translation of endometrial transcriptomics to the clinic yielded an objective definition of the limited time period …

0301 basic medicine030219 obstetrics & reproductive medicineendometrial receptivitybusiness.industryNatural cycleHormonal replacement therapyEmbryoimplantation / recurrent implantation failureDiseaseEndometriumPrecision medicineBioinformaticsAcademicSubjects/MED00905Embryo transfer03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureDebate ContinuedmedicineendometriumEndometrial receptivitybusinessembryo transferHuman Reproduction Open
researchProduct

Estrogenic regulation of skeletal muscle proteome : a study of premenopausal women and postmenopausal MZ cotwins discordant for hormonal therapy

2017

Female middle age is characterized by a decline in skeletal muscle mass and performance, predisposing women to sarcopenia, functional limitations, and metabolic dysfunction as they age. Menopausal loss of ovarian function leading to low circulating level of 17b-estradiol has been suggested as a contributing factor to aging-related muscle deterioration. However, the underlying molecular mechanisms remain largely unknown and thus far androgens have been considered as a major anabolic hormone for skeletal muscle. We utilized muscle samples from 24 pre- and postmenopausal women to establish proteome-wide profiles, associated with the difference in age (30–34 years old vs. 54– 62 years old), men…

0301 basic medicineAgingnaisetlabel‐free protein quantitationProteomeAnabolismvaihdevuodetmedicine.medical_treatmentTwinsmenopausenano‐LC‐HD‐MSElihakset0302 clinical medicineSTRENGTHBRAIN315 Sport and fitness sciencesta315luustoINHIBITORHormone replacement therapy (menopause)ta3142MITOCHONDRIAL BIOGENESISMiddle AgedPostmenopauseMenopauseREPLACEMENThormone replacement therapyEditorialmedicine.anatomical_structurehormonihoitoHormonal therapyOriginal ArticleFemalemuscleswomenAdultestrogeenitnano-LC-HD-MSEEXPRESSIONmedicine.medical_specialtyBiologyestrogenic regulation03 medical and health sciencesmitochondrial functionInternal medicinemedicineHumansMuscle Skeletallabel-free protein quantitationmuscle proteomeAgedSkeletal muscleEstrogenslabel-free proteinquantitationOriginal ArticlesCell Biologyfunctional annotationmedicine.diseaseMiddle ageMONOZYGOTIC TWIN PAIRS030104 developmental biologyEndocrinologyPremenopauselihasmassaSarcopeniaCELLS3111 BiomedicineEnergy Metabolismfemale muscle030217 neurology & neurosurgeryskeletal musclesHormone
researchProduct

Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to succ…

2019

Purpose: Agents targeting HR-positive, HER2-negative locally advanced or metastatic breast cancer have improved patient outcomes compared with conventional single-agent endocrine therapy. Currently, approved targeted agents include everolimus and three CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib. Unlike the well-characterized and easily manageable safety profile of endocrine therapies, adverse events associated with targeted therapies are complex and potentially severe. Their prompt recognition and treatment, crucial for prolonged endocrine sensitivity and survival, may be challenging and requires a multidisciplinary effort and a good knowledge of drug interactions. Methods:…

0301 basic medicineCancer ResearchReviewDiseasechemistry.chemical_compound0302 clinical medicineRibociclibMolecular Targeted TherapyAbemaciclibClinical Trials as TopicDisease ManagementMetastatic breast cancerEverolimuOncologyReceptors Estrogen030220 oncology & carcinogenesisFemaleAdvanced breast cancerReceptors ProgesteroneBreast Neoplasmmedicine.drugHumanmedicine.medical_specialtyNeutropeniaDrug-Related Side Effects and Adverse ReactionsAntineoplastic Agents HormonalProtein Kinase InhibitorBreast NeoplasmsPalbociclibPalbociclib03 medical and health sciencesBreast cancermedicineBiomarkers TumorHumansEverolimusIntensive care medicineAdverse effectProtein Kinase InhibitorsEverolimusbusiness.industrymedicine.diseaseClinical trialAbemaciclib030104 developmental biologychemistryMED/06 - ONCOLOGIA MEDICAbusinessDrug-Related Side Effects and Adverse ReactionAbemaciclib; Advanced breast cancer; Everolimus; Neutropenia; Palbociclib; Ribociclib
researchProduct

Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement

2019

AbstractBackgroundNeoadjuvant treatment is increasingly one of the preferred therapeutic options for early breast cancer and may have some unique outcomes, such as identifying predictive and prognostic factors of response or increasing the knowledge of individual tumor biology.DesignA panel of experts from different specialties reviewed published clinical studies on the neoadjuvant management of breast cancer. Recommendations were made that emphasized the clinical multidisciplinary management and the investigational leverage in early breast cancer.ResultsNeoadjuvant therapy has equivalent efficacy to adjuvant therapy, and it has some additional benefits that include increasing breast conser…

0301 basic medicineOncologyPosition statementCancer Researchmedicine.medical_specialtymedicine.medical_treatmentBreast Neoplasms03 medical and health sciences0302 clinical medicineBreast cancerInternal medicineBreast CancermedicineAdjuvant therapyHumansRadical surgeryskin and connective tissue diseasesNeoadjuvant therapyEarly breast cancerChemotherapybusiness.industrymedicine.diseaseNeoadjuvant Therapy030104 developmental biologyOncology030220 oncology & carcinogenesisHormonal therapyFemalebusinessThe Oncologist
researchProduct

A Standardized Wedelia chinensis Extract Overcomes the Feedback Activation of HER2/3 Signaling upon Androgen-Ablation in Prostate Cancer

2017

Crosstalk between the androgen receptor (AR) and other signaling pathways in prostate cancer (PCa) severely affects the therapeutic outcome of hormonal therapy. Although anti-androgen therapy prolongs overall survival in PCa patients, resistance rapidly develops and is often associated with increased AR expression and upregulation of the HER2/3-AKT signaling pathway. However, single agent therapy targeting AR, HER2/3 or AKT usually fails due to the reciprocal feedback loop. Previously, we reported that wedelolactone, apigenin, and luteolin are the active compounds in Wedelia chinensis herbal extract, and act synergistically to inhibit the AR activity in PCa. Here, we further demonstrated th…

0301 basic medicinenatural productsmedicine.drug_classPharmacologyurologic and male genital diseasesAntiandrogen03 medical and health scienceschemistry.chemical_compoundProstate cancer0302 clinical medicineHER3HER2LNCaPMedicineEnzalutamidePharmacology (medical)Pharmacologybusiness.industrylcsh:RM1-950apoptosisprostate cancerWedelolactonemedicine.diseaseAndrogenanimal modelsAndrogen receptorlcsh:Therapeutics. Pharmacology030104 developmental biologychemistry030220 oncology & carcinogenesisHormonal therapybusinessFrontiers in Pharmacology
researchProduct

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor–Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Ta…

2016

Purpose To describe estradiol (E2), estrone (E1), and estrone sulfate (E1S) levels during the first year of monthly triptorelin plus exemestane or tamoxifen and to assess possible suboptimal suppression while receiving exemestane plus triptorelin. Patients and Methods Premenopausal patients with early breast cancer on the Suppression of Ovarian Function Trial who selected triptorelin as the ovarian suppression method and were randomly assigned to exemestane plus triptorelin or tamoxifen plus triptorelin were enrolled until the target population of 120 patients was reached. Blood sampling time points were 0, 3, 6, 12, 18, 24, 36, and 48 months. Serum estrogens were measured with a highly sen…

Adult0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyAntineoplastic Agents HormonalEstronemedicine.drug_classBreast NeoplasmsEstrone03 medical and health scienceschemistry.chemical_compoundFollicle-stimulating hormone0302 clinical medicineBreast cancerExemestaneInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansGynecologyTriptorelin PamoateEstradiolbusiness.industryOvaryEstrogensORIGINAL REPORTSLuteinizing Hormonemedicine.diseaseTriptorelinAndrostadienesTamoxifen030104 developmental biologyOncologychemistryChemotherapy AdjuvantEstrogen030220 oncology & carcinogenesisFemaleFollicle Stimulating HormonebusinessTamoxifenmedicine.drugBlood samplingJournal of Clinical Oncology
researchProduct

Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women…

2016

PURPOSE: The 21-gene Recurrence Score assay (Oncotype DX) provides prognostic/predictive information in oestrogen receptor positive (ER+) early breast cancer, but access/reimbursement has been limited in most European countries in the absence of prospective outcome data. Recently, two large prospective studies and a real-life 5-year outcome study have been reported. We performed a pooled analysis of prospective European impact studies to generate robust data on impact of use in different clinical subgroups. METHODS: The analysis included four studies (French, German, Spanish, and British) in ER+ human epidermal growth factor receptor 2-negative breast cancer patients (n = 527). Node-positiv…

Adult0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyReceptor ErbB-2medicine.medical_treatmentClinical Decision-MakingBreast NeoplasmsMama -- Càncer -- TractamentRisk AssessmentSeverity of Illness Index03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancerInternal medicineQuimioteràpiaHumansMedicineProspective StudiesOestrogen receptorPrecision MedicineStage (cooking)Prospective cohort studyReimbursementAgedAged 80 and overGynecologyChemotherapyIndividualised medicinemedicine.diagnostic_testbusiness.industryGene Expression ProfilingMiddle Agedmedicine.diseaseTumor BurdenAdjuvant chemotherapyEurope030104 developmental biologyReceptors EstrogenOncology030220 oncology & carcinogenesisHormonal therapyFemaleNeoplasm Recurrence LocalbusinessOncotype DXClinical decision makingEuropean Journal of Cancer
researchProduct

The action of estrogens and progestogens in the young female breast

2018

Evidence from different sources sustains a pro-oncogenic role of hormones, estrogens and progestogens, on the breast. The issue is of interest for young women, who are exposed to the hormonal changes imposed by the ovarian cycle and, often, take hormones with contraceptive purposes. Experimental and clinical studies show that both estrogens and progesterone are involved in mammary development during puberty and lactation, the changes being observed across mammalian species, including humans. Estrogen receptors, and more particularly the alpha isoform, participate in molecular processes of stem cells differentiation and epithelial proliferation through paracrine actions implicating growth fa…

Adult0301 basic medicinemedicine.medical_specialtymedicine.drug_classEstrogen receptorBreast NeoplasmsContraceptives Oral HormonalYoung Adult03 medical and health sciences0302 clinical medicineBreast cancerInternal medicinemedicineHumansBreastAromataseAromatase inhibitorbiologybusiness.industryObstetrics and GynecologyEstrogensmedicine.disease030104 developmental biologyEndocrinologyPremenopauseReceptors EstrogenReproductive MedicineEstrogenSelective estrogen receptor modulator030220 oncology & carcinogenesisbiology.proteinFemaleProgestinsReceptors Progesteronebusinesshormones hormone substitutes and hormone antagonistsTamoxifenmedicine.drugHormoneEuropean Journal of Obstetrics & Gynecology and Reproductive Biology
researchProduct

Does Preoperative Treatment with a Gonadotropin-Releasing Hormone Agonist Improve the Outcome of Endometrial Resection?

1998

Abstract Study Objective. To verify if more favorable long-term results of endometrial resection can be obtained with preoperative gonadotropin-releasing hormone (GnRH) agonist treatment. Design. Multicenter, randomized, controlled trial (Canadian Task Force classification I). Setting. Tertiary care academic department. Patients. Sixty-three premenopausal women with established menorrhagia. Intervention. Eight weeks of goserelin depot treatment before endometrial resection or immediate surgery in the early proliferative phase of the cycle. Measurements and Main Results. Variations in menstrual patterns and bleeding scores as well as overall degree of satisfaction with treatment were determi…

AdultAgonistmedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classlaw.inventionEndometriumRandomized controlled triallawGonadotropin-releasing hormone agonistPreoperative CareFollicular phaseElectrocoagulationmedicineHumansProspective StudiesMenorrhagiabusiness.industryGoserelinObstetrics and GynecologyEndoscopyMiddle AgedSurgeryExact testTreatment OutcomeDelayed-Action PreparationsUterine NeoplasmsGoserelinFemaleAmenorrheamedicine.symptombusinessAdenomyomamedicine.drugHormone
researchProduct

Erratum: By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy

2019

Basal-like breast cancer is an aggressive tumor subtype with a poor response to conventional therapies. Tumor formation and relapse are sustained by a cell subset of Breast Cancer Stem Cells (BrCSCs). Here we show that miR-100 inhibits maintenance and expansion of BrCSCs in basal-like cancer through Polo-like kinase1 (Plk1) down-regulation. Moreover, miR-100 favors BrCSC differentiation, converting a basal like phenotype into luminal. It induces the expression of a functional estrogen receptor (ER) and renders basal-like BrCSCs responsive to hormonal therapy. The key role played by miR-100 in breast cancer free-survival is confirmed by the analysis of a cohort of patients' tumors, which sho…

AdultAntineoplastic Agents HormonalTransplantation HeterologousBreast cancer basal-like differentiation miR-100Breast NeoplasmsCell Cycle ProteinsKaplan-Meier EstimateMice SCIDProtein Serine-Threonine KinasesMice Inbred NODCell Line TumorProto-Oncogene ProteinsAnimalsHumansAgedAged 80 and overReverse Transcriptase Polymerase Chain ReactionCorrectionCell DifferentiationMiddle AgedPrognosisImmunohistochemistryGene Expression Regulation NeoplasticMicroRNAsTamoxifenOncologyReceptors EstrogenMCF-7 CellsNeoplastic Stem CellsFemale
researchProduct